Deepverge PLC Exercise of Warrants and Total Voting Rights (5404Q)

TIDMDVRG

RNS Number : 5404Q

Deepverge PLC

26 February 2021

26 February 2021

DeepVerge PLC

("DeepVerge" or "Company")

Exercise of Warrants

Provides GBP 443k additional working capital for Skin Trust Club launch

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, has received notification from warrant holders to exercise warrants over 1,230,708 shares in the share capital of DeepVerge ("the Subscriber Warrant Shares") at an exercise price of 20 pence. T he consideration for the exercise of the Subscriber Warrant Shares

amounts, in aggregate, to a cash value of   GBP246,141.60. 

In addition, the Company has received notification from its broker, Turner Pope Investments, to exercise warrants over 1,372,284 shares in the share capital of DeepVerge ("the Broker Warrant Shares") at an exercise price of 15 pence for 557,999 shares and at an exercise price of 14p for 814,285 shares. T he consideration for the exercise of the Broker Warrant Shares amounts, in aggregate, to a cash value of GBP197,699.75.

Gerard Brandon CEO of DeepVerge plc commented:

"DeepVerge has seen annual triple digit percentage revenue growth, culminating in excess of 330% in H2 2020 alone, and delivering GBP4.4m revenues for 2020. The recently announced production orders of GBP3.6m evidences the continued growth in line with guidance of GBP10m revenue from organic growth for 2021.

"We thank our Broker, Turner Pope Investments, for their continued support and confidence in DeepVerge. Working with long term shareholders, they coordinated the exercise of Broker and Subscriber Warrant Shares for 2018 and 2019 placings, removing a perceived overhang of shares which were due to expire on the 2nd May 2021. The Company has been further assured by our Broker and Subscriber Warrant Shareholders that the exercised shares are held by long term shareholders with no party having an immediate intention of disposal.

"As a result, this provides an additional GBP443,841 cash, and in combination with the undrawn debt of GBP1.5m available to the Company, provides a strong working capital base to enable continued sales growth from the expansion of our robust orderbook for 2021."

The Subscriber Warrant Shares and the Broker Warrants Shares ("the Warrant Shares") were allotted on 26 February 2021. Application will be made for the Warrant Shares to be admitted to trading on AIM ("Admission"), and Admission is expected to be on or about 4 March 2021. These shares will rank pari passu with the ordinary shares of the Company in issue.

Total voting rights

The Company's total issued capital, after the issue of the Warrant Shares, will be 172,857,347 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

Contacts

 
                                                   [phone] 
 DeepVerge plc              Gerard Brandon, CEO     648 
 
 SPARK Advisory Partners 
  Limited                   Neil Baldwin/Andrew    [phone] 
  (Nominated Adviser)        Emmott                 8974 
 
 Turner Pope Investments    Andy Thacker/Zoe       [phone] 
  (TPI) Limited (Broker)     Alexander              0050 
 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

Skin Trust Club (www.skintrustclub.com)

Customised skincare routine derived from a home test kit, lab tested and linked to local environment via a free smartphone App that updates in real-time and identifies ingredients that suit the subscribers unique skin microbiome. This revolutionises how you take care of your skin with your own skincare routine.

Home Test Kit comprises a single swab that maps the skin microbiome delivering a report that produces the most appropriate daily skincare routine based on science, not guesswork. Using real-time air pollution and weather data from the customer's location, the Skin Trust App builds a complete picture of the skin microbiome and the impact of local surroundings.

Skin Trust Analysis includes:

-- Microbiome identification and quantification of living organisms (bacteria, viruses, bacteriophages, fungi, parasites, etc.) on the skin;

-- Skin gene expression analysis to quantify the biological activity of living organisms on the skin;

   --      Analysis of metabolites in the skin sample; 

-- Personal genetic analysis - analyse genomic data to understand potential skin concerns and future risks but does not analyse genes to identify inherited diseases.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEGZGZZZVLGMZM

(END) Dow Jones Newswires

February 26, 2021 07:11 ET (12:11 GMT)